• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry.
CONCLUSION: Guideline adherence on stroke prevention was higher in Belgium than in the rest of Europe, and increased over time. NOAC use in Belgium was the highest of Europe at the study start, with many countries catching up later. Possible reasons are discussed. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov . Unique identifier: NCT01090362. PMID: 30369290 [PubMed - as supplied by publisher]
Source: Acta Cardiologica - October 31, 2018 Category: Cardiology Tags: Acta Cardiol Source Type: research

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
Conclusion: NOACs had better long-term risk-benefit profiles than VKAs. While effectiveness was comparable, apixaban was overall associated with a more favorable safety profile followed by dabigatran.
Source: Frontiers in Pharmacology - February 2, 2023 Category: Drugs & Pharmacology Source Type: research

The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
CONCLUSION: Polypharmacy was associated with increased thromboembolic, bleeding, and mortality risks in AF patients. NOACs had better benefit-risk profiles than VKAs in patients with polypharmacy.PMID:37369234 | DOI:10.1055/s-0043-1769735
Source: Thrombosis and Haemostasis - June 27, 2023 Category: Hematology Authors: Maxim Grymonprez Mirko Petrovic Tine L De Backer Stephane Steurbaut Lies Lahousse Source Type: research

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD-AF registry.
CONCLUSIONS: In GARFIELD-AF, despite similar characteristics, patients on anticoagulants were treated differently in NL and BE. Although the rate of major bleeding was 33% higher in NL, variations in bleeding, mortality and TE rates were not statistically significant. PMID: 32886853 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 3, 2020 Category: Hematology Authors: Seelig J, Hemels MEW, Xhaët O, Bongaerts MCM, de Wolf A, Groenemeijer BE, Heyse A, Hoogslag P, Voet J, Herrman JR, Vervoort G, Hermans W, Wollaert B, Boersma LVA, Hermans K, Lucassen A, Verstraete S, Adriaansen HJ, Mairesse GH, Terpstra WF, Faes D, Piete Tags: J Thromb Haemost Source Type: research

NOACs only for those who cannot tolerate a VKA: where is the evidence?
Authors: Bhagirath VC, Cosyns B, Eikelboom JW Abstract The 2016 European Society of Cardiology Guidelines recommend non-vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation. A recent report from the Belgian Healthcare Knowledge Centre (KCE) raised concerns about the results of the phase 3 randomised trials that led to the approval of the NOACs for this indication and concluded that NOACs should only be used for patients who fail or cannot undergo treatment with a vitamin K antagonist because they cannot achieve stable INR values. ...
Source: Acta Cardiologica - February 26, 2018 Category: Cardiology Tags: Acta Cardiol Source Type: research

Differences in knowledge among patients with atrial fibrillation receiving NOACs and vitamin K antagonists.
CONCLUSIONS: The knowledge of arrhythmia and anticoagulation is better regarding the safety issues among subjects on NOACs compared with VKA. Irrespective of the type of OAC therapy, education of AF patients should be improved. PMID: 29528483 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - March 12, 2018 Category: Cardiology Authors: Konieczyńska M, Sobieraj E, Bryk AH, Dębski M, Polak M, Podolec P, Małecka B, Pająk A, Desteghe L, Heidbuchel H, Undas A Tags: Kardiol Pol Source Type: research

Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
CONCLUSIONS: The knowledge of arrhythmia and anticoagulation is better regarding the safety issues among subjects on NOACs compared with those on VKAs. Irrespective of the type of oral anticoagulation therapy, education of AF patients should be improved. PMID: 29528483 [PubMed - indexed for MEDLINE]
Source: Kardiologia Polska - November 8, 2018 Category: Cardiology Authors: Konieczyńska M, Sobieraj E, Bryk AH, Dębski M, Polak M, Podolec P, Małecka B, Pająk A, Desteghe L, Heidbuchel H, Undas A Tags: Kardiol Pol Source Type: research

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care
ConclusionsInappropriate NOAC dosing is present in almost twenty percent of AF patients according to the SmPC and requires further education of health care professionals and frequent reassessment of NOAC dosing. However, a significant lower prevalence of underdosing was present when judged by the 2018 EHRA criteria, likely reflecting decision making in complex AF patients. Perceived frailty, weight, renal function and type of NOAC are the main determinants of deviated dosing.
Source: Clinical Drug Investigation - August 20, 2022 Category: Drugs & Pharmacology Source Type: research

Minimal Adherence Threshold to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation to Reduce the Risk of Thromboembolism and Death: A Nationwide Cohort Study
ConclusionPoor adherence to NOACs is associated with increased risks of thromboembolism and all-cause mortality. The minimal adherence threshold should be ≥ 90%, preferably even ≥ 95%.
Source: Cardiovascular Drugs and Therapy - September 14, 2023 Category: Cardiology Source Type: research